XML 26 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Revenues (Details Textual) (USD $)
3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Acetadote, Generic
Jun. 30, 2013
Acetadote, Generic
Jun. 30, 2013
Acetadote and Caldolor
Jun. 30, 2013
Milestone Method Future Revenue, Receipt of Regulatory Notice on Approval
Acetadote and Caldolor
Jun. 30, 2013
Non-collaborative Arrangement, 2013 Commercialization Agreement with Three International Partners
agreement
Jun. 30, 2013
Non-collaborative Arrangement, 2013 Commercialization Agreement with Three International Partners
agreement
Jun. 30, 2012
Collaborative Arrangement, Licensing Agreement with Harbin Gloria Pharmaceuticals Co. Ltd.
Acetadote and Caldolor
Dec. 31, 2012
Collaborative Arrangement, Licensing Agreement with Harbin Gloria Pharmaceuticals Co. Ltd.
Acetadote and Caldolor
Dec. 31, 2012
Maximum
Non-collaborative Arrangement, 2013 Commercialization Agreement with Three International Partners
Milestone Method Future Revenue, Receipt of Regulatory Notice on Approval
Dec. 31, 2012
Maximum
Non-collaborative Arrangement, 2013 Commercialization Agreement with Three International Partners
Milestone Method Future Revenue, Payments Based on Total and Annual Product Sales
Jun. 30, 2013
International
Jun. 30, 2012
International
Jun. 30, 2013
International
Jun. 30, 2012
International
Revenue from External Customer [Line Items]                                    
Product sales to international customers $ 7,081,088 $ 12,366,940 $ 17,339,220 $ 22,623,152                     $ 100,000 $ 100,000 $ 100,000 $ 100,000
Revenues (Textual) [Abstract]                                    
Share of product revenue from generic sales         2,100,000 5,000,000                        
Number of agreements with international partners for commercialization in international markets                 3 3                
Revenue recognized from license agreement                 200,000 600,000 700,000 700,000            
Other revenues, milestone method, future revenue upon achieving milestones                         500,000 3,700,000        
Agreed future payments under licensing agreement once milestone achieved             700,000                      
Additional milestone payments to be received               $ 1,100,000